Currently, ranibizumab (LucentisTM) and bevacizumab (AvastinTM), both antivascular endothelial growth factor (anti-VEGF) recombinant humanized monoclonal antibodies, and aflibercept (EyleaTM), a fusion protein that includes extracellular domains of VEGF receptors 1 and 2, have demonstrated their efficacy in CNV, secondary to AMD patients. Here, VEGFA is linked to age-related macular degeneration.